NM_024675.4:c.2993G>A

Variant names:

Variant summary

Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_024675.4(PALB2):c.2993G>A(p.Gly998Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0197 in 1,614,050 control chromosomes in the GnomAD database, including 389 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.017 ( 41 hom., cov: 32)

Exomes 𝑓: 0.020 ( 348 hom. )

Consequence

PALB2
NM_024675.4 missense

Scores

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts P:1B:27O:1

Conservation

PhyloP100: 3.23

Variant links:

Genes affected

PALB2 (HGNC:26144): (partner and localizer of BRCA2) This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2. [provided by RefSeq, Jul 2008]

PALB2 links:

ENSG00000261723 (HGNC:58305):

ENSG00000261723 links:

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -20 ACMG points.

BP4

Computational evidence support a benign effect (MetaRNN=0.0049796402).

BP6

Variant 16-23622972-C-T is Benign according to our data. Variant chr16-23622972-C-T is described in ClinVar as [Likely_benign]. Clinvar id is 126699.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-23622972-C-T is described in Lovd as [Likely_benign]. Variant chr16-23622972-C-T is described in Lovd as [Benign].

BS1

Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.0171 (2602/152274) while in subpopulation NFE AF= 0.0227 (1547/68026). AF 95% confidence interval is 0.0218. There are 41 homozygotes in gnomad4. There are 1272 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.

BS2

High Homozygotes in GnomAd4 at 41 AD,AR gene

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
PALB2	NM_024675.4 link	c.2993G>A	p.Gly998Glu	missense_variant	Exon 9 of 13	ENST00000261584.9	NP_078951.2	Q86YC2

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
PALB2	ENST00000261584.9 link	c.2993G>A	p.Gly998Glu	missense_variant	Exon 9 of 13	1	NM_024675.4	ENSP00000261584.4		Q86YC2

Frequencies

GnomAD3 genomes

AF:

0.0171

AC:

2605

AN:

152156

Hom.:

Cov.:

show subpopulations

Gnomad AFR

AF:

0.00459

Gnomad AMI

AF:

0.147

Gnomad AMR

AF:

0.0220

Gnomad ASJ

AF:

0.0302

Gnomad EAS

AF:

0.000192

Gnomad SAS

AF:

0.00744

Gnomad FIN

AF:

0.0168

Gnomad MID

AF:

0.0886

Gnomad NFE

AF:

0.0227

Gnomad OTH

AF:

0.0244

GnomAD3 exomes

AF:

0.0164

AC:

4123

AN:

251452

Hom.:

AF XY:

0.0168

AC XY:

2288

AN XY:

135902

show subpopulations

Gnomad AFR exome

AF:

0.00437

Gnomad AMR exome

AF:

0.0136

Gnomad ASJ exome

AF:

0.0232

Gnomad EAS exome

AF:

0.0000544

Gnomad SAS exome

AF:

0.00944

Gnomad FIN exome

AF:

0.0188

Gnomad NFE exome

AF:

0.0222

Gnomad OTH exome

AF:

0.0212

GnomAD4 exome

AF:

0.0199

AC:

29158

AN:

1461776

Hom.:

348

Cov.:

AF XY:

0.0198

AC XY:

14384

AN XY:

727196

show subpopulations

Gnomad4 AFR exome

AF:

0.00358

Gnomad4 AMR exome

AF:

0.0145

Gnomad4 ASJ exome

AF:

0.0240

Gnomad4 EAS exome

AF:

0.0000504

Gnomad4 SAS exome

AF:

0.0101

Gnomad4 FIN exome

AF:

0.0182

Gnomad4 NFE exome

AF:

0.0221

Gnomad4 OTH exome

AF:

0.0193

GnomAD4 genome

AF:

0.0171

AC:

2602

AN:

152274

Hom.:

Cov.:

AF XY:

0.0171

AC XY:

1272

AN XY:

74448

show subpopulations

Gnomad4 AFR

AF:

0.00457

Gnomad4 AMR

AF:

0.0219

Gnomad4 ASJ

AF:

0.0302

Gnomad4 EAS

AF:

0.000193

Gnomad4 SAS

AF:

0.00745

Gnomad4 FIN

AF:

0.0168

Gnomad4 NFE

AF:

0.0227

Gnomad4 OTH

AF:

0.0241

Alfa

AF:

0.0220

Hom.:

Bravo

AF:

0.0177

TwinsUK

AF:

0.0235

AC:

ALSPAC

AF:

0.0205

AC:

ESP6500AA

AF:

0.00592

AC:

ESP6500EA

AF:

0.0240

AC:

206

ExAC

AF:

0.0158

AC:

1917

Asia WGS

AF:

0.00404

AC:

AN:

3478

EpiCase

AF:

0.0306

EpiControl

AF:

0.0278

ClinVar

Significance: Benign/Likely benign

Submissions summary: Pathogenic:1Benign:27Other:1

Revision: criteria provided, multiple submitters, no conflicts

LINK: link

Submissions by phenotype

not specified

Benign:6Other:1

Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute

Significance: Benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Sep 19, 2013

ITMI

Significance: not provided

Review Status: no classification provided

Collection Method: reference population

- -

Mar 04, 2025

Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

PreventionGenetics, part of Exact Sciences

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Genome Diagnostics Laboratory, Amsterdam University Medical Center

Significance: Benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Oct 14, 2013

GeneDx

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+

Significance: Benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Familial cancer of breast

Benign:6

Feb 04, 2025

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Apr 01, 2016

Counsyl

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Nov 06, 2014

Pathway Genomics

Significance: Benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

May 28, 2019

Mendelics

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Mar 31, 2023

Myriad Genetics, Inc.

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant is considered benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. -

Jun 01, 2015

Cancer Genetics Laboratory, Peter MacCallum Cancer Centre

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: case-control

- -

not provided

Benign:5

Nov 03, 2021

Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Oct 16, 2024

ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Aug 07, 2019

Leiden Open Variation Database

Significance: Benign

Review Status: no assertion criteria provided

Collection Method: curation

Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitters to LOVD: Marc Tischkowitz, Maximiliano Zeballos, Melissa DeRycke. -

Breakthrough Genomics, Breakthrough Genomics

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: not provided

- -

Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)

Significance: Likely benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome

Benign:5

May 11, 2021

Sema4, Sema4

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: curation

- -

Oct 26, 2015

Vantari Genetics

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Jun 10, 2014

Ambry Genetics

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Feb 14, 2017

Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C.

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Feb 23, 2018

True Health Diagnostics

Significance: Likely benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Ovarian cancer

Pathogenic:1

Jan 01, 2022

Laboratory of Molecular Epidemiology of Birth Defects, West China Second University Hospital, Sichuan University

Significance: Likely pathogenic

Review Status: flagged submission

Collection Method: clinical testing

- -

Familial cancer of breast;C1835817:Fanconi anemia complementation group N;C3150547:Pancreatic cancer, susceptibility to, 3

Benign:1

Aug 06, 2021

Fulgent Genetics, Fulgent Genetics

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Fanconi anemia complementation group N

Benign:1

Mar 06, 2018

Illumina Laboratory Services, Illumina

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Breast-ovarian cancer, familial, susceptibility to, 5

Benign:1

Jul 07, 2023

KCCC/NGS Laboratory, Kuwait Cancer Control Center

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Malignant tumor of breast

Benign:1

Department of Pathology and Laboratory Medicine, Sinai Health System

Significance: Likely benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

The PALB2 p.Gly998Glu variant was identified in 268 of 12272 proband chromosomes (freq 0.022) in multinational cohorts of BRCA1 and BRCA2 negative breast and breast-ovarian cancer families, male breast cancer cases, women with breast cancer who had a personal or family history of pancreatic cancer, families with 2 or more prostate cancer cases, unselected breast and ovarian cancers, and American hereditary prostate cancer families; and was identified in 129 of 7352 control chromosomes (freq. 0.018) (Balia 2010, Blanco 2012, Bogdanova 2011, Cao 2009, Catucci 2014, Ding 2011, Downs 2015 , Garcia 2009, Guenard 2010, Hofstatter 2011, Kuusisto 2011, Leyton 2015 , Pakkanen 2009, Prokofyeva 2012, Hellebrand 2011, Rahman 2007, Sauty de Chalon 2010, Silvestri 2010, Sluiter 2009, Teo 2013, Wong 2011, Tischkowitz 2008, Zheng 2012). Blanco et al (2012) identified the variant in 6 index cases, which also had 5 other PALB2 variants, with co-segregation analysis in one of the carriers suggesting that all 6 variants constituted a haplotype. In a study looking at BRCA1 positive and BRCA negative families, the PALB2 variant was found in 2 families who carried different BRCA1 mutations (332-11T-Gins59-ter75, and 300Cys-Gly (T-G)) (Downs 2015 ). In their study, Rahman et al (2007) found no overall evidence that PALB2 missense variants confer susceptibility to breast cancer, with 23% affected individuals and 24% controls carrying at least one nonsynonymous missense variant. The variant was also identified in dbSNP (ID: rs45551636) as â€šÃ„Ãºotherâ€šÃ„Ã¹ allele, Clinvitae database (classifications benign, likely benign, conflicting interpretations of pathogenicity), Fanconi Anemia Mutation Database (LOVD), the ClinVar database (classifications benign: Invitae, Ambry Genetics, Prevention Genetics, Counsyl, GeneDx, Pathway Genomics, PALB2 database , likely benign: Vantari Genetics, Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Illumina Clinical Services Laboratory , and not provided: ITMI submitters). The variant was identified in control databases in 1917 of 121404 chromosomes at a frequency of 0.01579 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Consortium Feb 27, 2017). The variant was identified in the following populations at a frequency greater than 1%: Ashkenazi Jewish* in 237 of 10150 chromosomes (freq: 0.023), European (Non-Finnish) in 2781 of 126704 chromosomes (freq: 0.022), Other in 129 of 6466 chromosomes (freq: 0.02), European (Finnish) in 481 of 25784 chromosomes (freq: 0.019), Latino in 471 of 34418 chromosomes (freq: 0.014). The p.Gly998 residue is conserved across mammals and other organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. -

Hereditary breast ovarian cancer syndrome

Benign:1

Apr 19, 2022

National Health Laboratory Service, Universitas Academic Hospital and University of the Free State

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

AlphaMissense

Benign

0.26

BayesDel_addAF

Benign

-0.41

BayesDel_noAF

Benign

-0.34

CADD

Uncertain

DANN

Uncertain

1.0

DEOGEN2

Benign

0.15

T;T

Eigen

Pathogenic

0.73

Eigen_PC

Pathogenic

0.71

FATHMM_MKL

Uncertain

0.91

LIST_S2

Benign

0.82

T;T

MetaRNN

Benign

0.0050

T;T

MetaSVM

Benign

-0.91

MutationAssessor

Uncertain

2.6

.;M

PrimateAI

Benign

0.41

PROVEAN

Pathogenic

-6.1

D;D

REVEL

Benign

0.29

Sift

Uncertain

0.0030

D;D

Sift4G

Pathogenic

0.0

D;D

Polyphen

1.0

.;D

Vest4

0.28

MPC

0.38

ClinPred

0.012

GERP RS

5.8

Varity_R

0.80

gMVP

0.63

Splicing

Name

Calibrated prediction

Score

Prediction

SpliceAI score (max)

0.0

Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

LitVar

Other links and lift over